Loading
ProDa BioTech is a company in Marietta, Georgia, developing ProAgio, a protein drug that kills cells carrying an integrin receptor in tumours and the tissue around them. ProAgio is in an early trial with chemotherapy in triple-negative breast cancer that has spread.
ProDa BioTech, LLC, of Marietta, Georgia, sponsors the phase 1/2 trial NCT06460298, which the registry describes as evaluating ProAgio, an anti-alpha-v-beta-3 integrin cytotoxin, with gemcitabine in metastatic triple-negative breast cancer. In fiscal year 2026 NCI awarded it USD 1,139,113 under SBIR grant 1R44CA314813-01 to develop a new combination therapy for pancreatic ductal adenocarcinoma; the abstract describes depleting cancer-associated fibroblasts and pancreatic stellate cells, which lay down the dense stroma that limits drug delivery, and altering abnormal tumour vessels.
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI SBIR Phase II (R44) award 1R44CA314813-01: Development of a new combination therapy for pancreatic ductal adenocarcinoma treatment | 2026 | $1M | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
ProAgio is a protein drug from ProDa BioTech that targets an integrin receptor found on tumour blood vessels and the support cells around tumours. It is in an early trial with gemcitabine in triple-negative breast cancer that has spread.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/